This clinical trial investigates the effectiveness of 3 medications: brexpiprazole, memantine and zinc in treating anorexia nervosa (AN). Building on preliminary evidence suggesting these medications' role in mood, cognition, and eating disorder behaviours, this study aims to explore the therapeutic potential in addressing the multifaceted symptoms of AN.\
\
Trial objective:

1. Evaluate the effectiveness of brexpiprazole, memantine and zinc in improving psychological symptoms of AN from baseline to end of treatment (12 weeks) as compared to placebo.
2. Assess the impact of these medications on stabilising and increasing body mass from baseline to end of treatment.

Trial Design & Procedure:\
This clinical trial will enrol 100 participants who will be randomly assigned to receive either brexpiprazole, memantine, zinc or a placebo, for a duration of 12 weeks (1x capsule daily). Participants’ eating disorder symptoms and broader psychological symptoms will be measured every 4 weeks.\
\
Potential Benefits & Positive Outcomes:\
Demonstrate the effectiveness of brexpiprazole, memantine and zinc in improving psychological symptoms and body mass in AN.\
Provide insights into brexpiprazole, memantine and zinc’s role in mood and cognition, and their regulatory effects on eating disorder behaviours.\
Offer novel, potentially more effective treatment options for AN, addressing the urgent need for innovative therapeutic strategies in this challenging and often chronic condition.

Recruitment details\
To find out more about participating in a Li-THRED Treatment Trial\
Email us: THRED@monash.edu\
Or phone us: (03) 9076 9802

Eligibility criteria:\
-Current diagnosis of AN, Atypical AN, or AN in partial remission (can be assessed at screening if not formally diagnosed)

• Age 16 or older
• No contraindications to study medications